Add 2 More Reports For 20% off

Report Overview

2023

Base Year

2017-2023

Historical Year

2024-2032

Forecast Year

Middle East and Africa Generic Drugs Market Size

The Middle East and Africa generic drugs market was valued at USD 33 billion in 2023, driven by increasing healthcare needs and strategic partnerships in the region. The market is expected to grow at a CAGR of 7.42% during the forecast period of 2024-2032, with the values likely to rise from USD 35.4 billion in 2024 to USD 62.8 billion by 2032.

Middle East and Africa Generic Drugs Market Outlook

  • The rising healthcare needs in Middle Eastern and African countries, due to the growing burden of chronic diseases and population growth are poised to augment the market demand.
  • One of the major Middle East and Africa generic drugs market trends is the rise in strategic partnerships between local and international pharmaceutical companies. For instance, in September 2023, Cipla Limited signed an agreement to acquire Actor Pharma (Pty) Ltd, a South African over the counter (OTC) and generic medicines pharmaceutical company to gain entry into the South African market and strengthen its OTC drug offerings.
  • Healthcare policies in the Middle East and North Africa region are increasingly focusing on reducing healthcare expenditure which is shifting the focus on improving the accessibility and uptake of affordable treatment options, thereby elevating the market value.

Middle East and Africa Generic Drugs Market Analysis

A generic drug contains the same active ingredients and offers similar clinical benefits as a brand-name medicine. They are generally marketed at lower prices (an estimated 80 to 85% less ) and thus serve as a cost-effective alternative to patent-protected medications. Healthcare policies in the Middle East and North Africa region are increasingly focusing on reducing healthcare expenditure which is shifting the focus on improving the accessibility and uptake of affordable treatment options, such as generic drugs. Further, the rising investment in healthcare infrastructure, such as hospitals and clinics, especially in under-developed areas, is expected to fuel the Middle East and Africa Generic Drugs market in the coming years.

The rising healthcare needs in the Middle Eastern and African countries, due to the growing burden of chronic diseases and population growth, are significantly contributing to the expansion of the global generic drugs market . The International Diabetes Federation states that diabetes prevalence in the region is projected to reach 136 million cases by 2045. Additionally, obesity is a severe problem in the Middle East and Africa, comprising 18 of the top 50 countries with high obesity rates globally.  With the growing prevalence of chronic conditions (needing long-term medications), the Middle East and Africa Generic Drugs market demand is expected to witness a surge in the forecast period.

One of the major market trends is the rise in strategic partnerships between local and international pharmaceutical companies. For instance, in September 2023 , Cipla Limited, an Indian multinational pharmaceutical company signed an agreement to acquire Actor Pharma (Pty) Ltd, a South African-based pharmaceutical company specializing in over the counter (OTC) and generic medicines, at a deal worth USD 48.6 million . The acquisition was intended to enter the South African market and strengthen its OTC drug offerings. Such collaborations also allow the regional players to utilize advanced technology and expertise, which helps them to improve the manufacturing efficiency and quality of generic drugs. Thus, the increasing merger and acquisition activities are anticipated to boost the market share.

Middle East and Africa Generic Drugs Market Segmentation

The report offers a detailed analysis of the market based on the following segments:

Market Breakup     Categories
Therapy Area Cardiovascular, Dermatology, Respiratory, Oncology, Rheumatology, Others
Route of Administration Oral, Injectables, Dermal/Topical, Inhalers, Others
Distribution Channels Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others
Country Saudi Arabia, Egypt, Others

Leading Players in the Middle East and Africa Generic Drugs Market

The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

  • Teva Pharmaceutical Industries Ltd
  • Viatris Inc.
  • AstraZeneca
  • Baxter
  • GSK plc
  • Bausch + Lomb
  • Novartis AG
  • Sanofi
  • Pfizer Inc.
  • Fresenius SE & Co. KGaA
  • Hikma Pharmaceuticals PLC

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Therapy Area
  • Route of Administration
  • Distribution Channels
  • Region
Breakup by Therapy Area
  • Cardiovascular
  • Dermatology
  • Respiratory
  • Oncology
  • Rheumatology 
  • Others
Breakup by Route of Administration
  • Oral
  • Injectables
  • Dermal/Topical
  • Inhalers
  • Others
Breakup by Distribution Channels
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others
Breakup by Region
  • UAE
  • Saudi Arabia
  • Egypt
  • Others
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Teva Pharmaceutical Industries Ltd
  • Viatris Inc.
  • AstraZeneca
  • Baxter
  • GSK plc
  • Bausch + Lomb
  • Novartis AG
  • Sanofi
  • Pfizer Inc.
  • Fresenius SE & Co. KGaA
  • Hikma Pharmaceuticals PLC

Middle East and Africa Generic Drugs Market Report Snapshots

Middle East and Africa Generic Drugs Market Size

Middle East and Africa Generic Drugs Market Analysis

Middle East and Africa Generic Drugs Companies

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Key Questions Answered in the Report

The market attained a value of about USD 33 billion in 2023 driven by increasing healthcare needs and strategic partnerships in the region.

The market is anticipated to grow at a CAGR of 7.42% during the forecast period of 2024-2032, likely to reach a market value of USD 62.8 billion by 2032.  

The rising burden of chronic diseases and the growing population size are fuelling the demand for the market.

One of the significant trends in the market is the increasing merger and acquisition activities among key market players. To gain entry into the South African market and strengthen its OTC drug offerings, Cipla Limited signed an agreement to acquire Actor Pharma (Pty) Ltd, a South African OTC and generic medicines pharmaceutical company in September 2023. 

Based on the therapy area, the market is segmented into cardiovascular, dermatology, respiratory, oncology, and rheumatology, among others.

By route of administration, the market is divided into oral, injectables, dermal/topical, and inhalers, among others.

The distribution channels of the market are hospital pharmacies, retail pharmacies, and online pharmacies, among others.

The market segmentation by countries includes UAE, Saudi Arabia, and Egypt, among others.

The key players in the market are Teva Pharmaceutical Industries Ltd., Viatris Inc., AstraZeneca, Baxter, GSK plc, Bausch + Lomb, Novartis AG, Sanofi, Pfizer Inc., Fresenius SE & Co. KGaA, and Hikma Pharmaceuticals PLC.

Purchase Full Report

Datasheet

 

USD 2,639

USD 2,299

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 4,399

USD 3,699

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 5,829

USD 4,899

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 6,929

USD 5,899

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us

Our Offices


Australia

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63-287-899-028, +63-967-048-3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.

+63-287-899-028, +63-967-048-3306

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124